Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5441 Health Center Drive
Abilene, TX 79606Phone+1 325-673-9806Fax+1 325-673-9809
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Ophthalmology, 1992 - 1995
Texas Health Resources (Dallas)Internship, Internal Medicine, 1991 - 1992
University of Texas Southwestern Medical SchoolClass of 1991
Certifications & Licensure
CA State Medical License 1993 - 2026
TX State Medical License 1997 - 2025
IL State Medical License 2010 - 2017
NJ State Medical License 2007 - 2017
NY State Medical License 1998 - 2017
OH State Medical License 2007 - 2012- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Start of enrollment: 2010 Jun 01
- Pilot Study of X-82 in Patients With Wet AMD Start of enrollment: 2012 Oct 01
- Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD Start of enrollment: 2015 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 243 citationsC5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Glenn J. Jaffe, Keith Westby, Karl G. Csaky, Jordi Monés, Joel A. Pearlman
Ophthalmology. 2021-04-01 - 1185 citationsRanibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDEQuan Dong Nguyen, David M. Brown, Dennis M. Marcus, David S. Boyer, Sunil S. Patel
Ophthalmology. 2012-04-01 - 613 citationsLong-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.David M. Brown, Quan Dong Nguyen, Dennis M. Marcus, David S. Boyer, Sunil S. Patel
Ophthalmology. 2013-10-01
Journal Articles
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationPravin U Dugel, Sunil S Patel, JAMA Ophthalmology
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Join now to see all
Press Mentions
Graybug Vision Expands Executive Team with Appointments of Charles P. Semba, MD, and Ward M. Peterson, PhDJune 21st, 2016
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
